ALL MULTIPLEX PANEL (t(9;22),t(12;21),t(1;19),t(4;11)
- Report in 1 hr
- Serum
₹6,000
Price
₹23,000
or call 77900 98009
AML PANEL - ADVANCE
₹23,000
The AML Panel – Advance is a molecular test that detects key gene mutations and fusions in acute myeloid leukemia (AML). These commonly include FLT3, NPM1, CEBPA, IDH1/IDH2, KIT, and TP53, and fusions such as PML-RARA, RUNX1-RUNX1T1, and CBFB-MYH11.
Results help classify AML and assess risk using ELN guidelines. NPM1 and CEBPA mutations often indicate a favorable prognosis, while FLT3-ITD and TP53 suggest higher risk.
It identifies patients for targeted therapies (FLT3 or IDH inhibitors), guides stem cell transplant decisions, and supports MRD monitoring.
An AML Panel – Advance is advised by a hematologist at the time of diagnosis of acute myeloid leukemia (AML), or when blood or bone marrow tests show myeloid blast cells. It is done before starting treatment to assess risk and identify targeted therapies, and may be repeated at relapse or to monitor response.
No fasting is required for an AML Panel – Advance done on a blood sample. If a bone marrow sample is needed, inform your doctor about blood thinners or bleeding disorders, and fast only if sedation is planned. Ideally, give the sample before starting chemotherapy. Samples must reach the lab promptly for accurate results.
No, fasting is not required for an AML Panel – Advance when a blood sample is used. You can eat and drink normally. However, if the test is done on a bone marrow sample under sedation, you may need to fast for 4–6 hours. Follow your doctor’s specific instructions.
₹6,000
₹10,000
₹8,000
₹15,000
Tell us what your doctor has prescribed and our team will confirm the right test and book it for you.